? HIV CURE SWG The HIV Cure Scientific Working Group is designed to provide a platform for generating new research in the area of HIV cure and also to create an environment to mentor and support young investigators. UNC has become an important center of cure research, hosting one of the Delaney Collaboratories, a multi-institution effort that includes Merck Pharmaceutical investigators. In addition the HIV Cure Center was recently formed as a private-public partnership with GSK. UNC also has significant strengths drug discovery, pharmacology, the regulation of chromatin modification, and expanding expertise in HIV immunology looking ahead to therapeutic vaccinations. The first goal of the HIV Cure SWG is to bring together this diverse set of investigators, including collaborators at other CFARs through video conferencing and from industry, to share data and explore ideas for new research pathways. The second goal of the HIV Cure SWG is to mentor and support new investigators on their path to independence. Taken together these two goals will advance cure research in the present and prepare the next generation of cure researchers for their own successes in the future. The HIV Cure SWG will be led by Dr. David Margolis, who also leads the Delaney Care Collaboratory and the HIV Cure Center, and by Dr. Andrew Spaltenstein, who is Vice President of the HIV Discovery Performance Unit of GSK and a new member of the HIV Cure Center.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI050410-21
Application #
9532774
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
21
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ford, Catherine; Chibwesha, Carla J; Winston, Jennifer et al. (2018) Women's decision-making and uptake of services to prevent mother-to-child HIV transmission in Zambia. AIDS Care 30:426-434
Edwards, Jessie K; Cole, Stephen R; Hall, H Irene et al. (2018) Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens. AIDS 32:261-266
Power, Jennifer; Westle, Andrew; Dowsett, Gary W et al. (2018) Perceptions of HIV cure research among people living with HIV in Australia. PLoS One 13:e0202647
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Scheidell, Joy D; Quinn, Kelly; McGorray, Susan P et al. (2018) Childhood traumatic experiences and the association with marijuana and cocaine use in adolescence through adulthood. Addiction 113:44-56
Tang, Weiming; Mao, Jessica; Liu, Chuncheng et al. (2018) Reimagining Health Communication: A Non-Inferiority Randomized Controlled Trial of Crowdsourced intervention in China. Sex Transm Dis :
Evon, D M; Amador, J; Stewart, P et al. (2018) Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther 47:1001-1011
Weber, Michael D; Andrews, Elizabeth; Prince, Heather A et al. (2018) Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women. Antivir Ther 23:495-504
Wang, Cheng; Mollan, Katie R; Hudgens, Michael G et al. (2018) Generalisability of an online randomised controlled trial: an empirical analysis. J Epidemiol Community Health 72:173-178
Garrido, Carolina; Abad-Fernandez, Maria; Tuyishime, Marina et al. (2018) Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. J Virol 92:

Showing the most recent 10 out of 1688 publications